Lota Zoth Recognized for Corporate and Community Accomplishments
GAITHERSBURG, Md., Dec. 7 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) announced today that the Washington Business Journal has
recognized Lota Zoth as one of the region's most influential business women at
an inaugural "Women Who Mean Business" awards reception held recently in
Washington, D.C. Ms. Zoth is the senior vice president and chief financial
officer at MedImmune, and is responsible for oversight of finance, information
management and corporate communications.
The "Women Who Mean Business" award honors women who have made lasting
contributions to Washington business through innovation, outstanding
performance and meaningful community involvement. Ms. Zoth was among 49
diverse honorees representing more than a dozen industries ranging from
hospitality to biotechnology. The honorees were selected from a pool of more
than 200 nominations.
"We are proud that the Washington Business Journal has recognized Lota's
outstanding contributions to MedImmune and to the community," said David M.
Mott, chief executive officer. "Lota's professional accomplishments,
dedication to her work and commitment to the corporate community establish her
as an exemplary leader in our company and in the biotechnology industry."
Ms. Zoth was honored for her professional accomplishments and her
commitment to community service. At MedImmune, she plays an integral role in
broadening the company's professional development initiatives for employees.
She encourages professional growth and team-building within the organization
and serves as a mentor to her colleagues. Ms. Zoth has spearheaded MedImmune's
community relations initiatives including company-wide participation in The
Leukemia and Lymphoma Society's "Light the Night" walk and the Salvation
Army's annual "Giving Tree" program.
A Texas native, Ms. Zoth is a certified public accountant, and holds a
bachelor's of business administration in accounting from Texas Tech
University.
About MedImmune
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With approximately 1,900 employees
worldwide, MedImmune is headquartered in Maryland. For more information, visit
the company's website at http://www.medimmune.com.
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the company's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance were received, such products would
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
-0- 12/07/2004
/CONTACT: Media: Jamie Lacey, +1-301-398-4035 or Investors: Peter Vozzo,
+1-301-398-4358 or John Filler, +1-301-398-4086, all of MedImmune/
/Web site: http://www.medimmune.com/
(MEDI)
CO: MedImmune, Inc.
ST: Maryland
IN: HEA MTC BIO PUB
SU: WOM AWD
MB-JA
-- DCTU051 --
5074 12/07/2004 14:59 EST http://www.prnewswire.com